[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356773-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356773-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","visualized-clinical-radiomics-model-based-on-non-contrast-computed-tomography-for-predicting-efficacy-of-surufatinib-in-hepatic-metastases-of-neuroendocrine-neoplasms","Visualized Clinical-Radiomics Model Based on Non-Contrast Computed Tomography for Predicting Efficacy of Surufatinib in Hepatic Metastases of Neuroendocrine Neoplasms","","Hepatic metastatic neuroendocrine neoplasms (HM-NENs) have limited treatment biomarkers and low survival, motivating a more precise response assessment. A retrospective fusion approach combines radiomics features extracted from pretreatment non-contrast computed tomography (NCCT) with clinical variables to predict Surufatinib efficacy. Using ROI manual segmentation, LASSO selects radiomics features and a clinical-radiomics logistic regression model is built and visualized as a nomogram.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/visualized-clinical-radiomics-model-based-on-non-contrast-computed-tomography-for-predicting-efficacy-of-surufatinib-in-hepatic-metastases-of-neuroendocrine-neoplasms/356773/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/visualized-clinical-radiomics-model-based-on-non-contrast-computed-tomography-for-predicting-efficacy-of-surufatinib-in-hepatic-metastases-of-neuroendocrine-neoplasms/356773.png","ImageObject",300,407,{"name":42,"@type":43},"Putri","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is predicting Surufatinib efficacy in HM-NENs clinically important?","Question",{"text":63,"@type":64},"HM-NENs have few effective biomarkers and poorer survival outcomes. Predicting treatment response supports more accurate precision medicine decisions.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the clinical-radiomics fusion model constructed?",{"text":68,"@type":64},"Pretreatment NCCT radiomics features were extracted after manual ROI segmentation. LASSO selected features, and multivariable logistic regression combined Radscore with clinical characteristics to form a nomogram.",{"name":70,"@type":61,"acceptedAnswer":71},"What performance did the fusion model achieve?",{"text":72,"@type":64},"The model reached an AUC of 0.926 (95% CI: 0.881–0.971) for response prediction, with bootstrap-verified AUC of 0.926 (95% CI: 0.880–0.966).","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356773,1790181472,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":113,"preview_page_count":33,"preview_urls":145},962085571259,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Cancer Medicine  \nRESEARCH ARTICLE  OPEN ACCESS   \nVisualized Clinical-Radiomics Model Based on Non-Contrast Computed Tomography for Predicting Efficacy of Surufatinibin Hepatic Metastases of Neuroendocrine Neoplasms  \nMiaomiao Feng1  | Man Zhao1 | Xiaoling Duan1 | Jiaojiao Hou1 | Qi Wang2 | Fei Yin1   \n1Department of Gastroenterology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China | 2Department of CT and MRI, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China  \nCorrespondence: Fei Yin ([47100214@hebmu.edu.cn](47100214@hebmu.edu.cn))  \nReceived: 18 July 2025 | Revised: 13 January 2026 | Accepted: 4 May 2026  \nKeywords: clinical-radiomics model | efficacy | hepatic metastatic neuroendocrine neoplasms | non-contrast computed tomography | surufatinib  \nABSTRACT  \nBackground: Hepatic metastatic neuroendocrine neoplasms (HM-NENs) have few treatment biomarkers and low survival rates. We created a clinical-radiomics fusion model based on non-contrast computed tomography (NCCT) to predict Surufatinib efficacy in HM-NENs. We presented it as a nomogram, meeting unmet requirements in precision medicine.  \nMethods: This retrospective study included 76 HM-NEN patients (131 hepatic metastases) treated with Surufatinib. Regions of interest (ROI) were manually segmented, and the best response to Surufatinib was decided based on Modified Response Evaluation Criteria in Solid Tumor (mRECIST) . Radiomics features were extracted from the pretreatment NCCT. The Least Absolute Shrinkage and Selection Operator (LASSO) was used to select radiomics features and calculate a Radiomics score (Radscore) . Multivariable logistic regression analysis was utilized to create the clinical-radiomics fusion model, which included clinical characteristics and Radscore and was displayed as a nomogram. The area under the receiver operating characteristic curve (ROC) was used to assess model performance, and internal validation was done using the bootstrap resampling approach. Results: After multivariate logistic regression analysis, the Radscore, the diameter of hepatic metastasis, the number of hepatic metastases, and extrahepatic metastasis were included as predictors in the final model. The area under the curve (AUC) of the clinical-radiomics fusion model to predict the response of Surufatinib of HM-NENs was 0.926 (95% confidence interval [CI]: 0.881–0.971). The AUC verified by bootstrap was 0.926 (95% CI: 0.880–0.966), indicating a good performance of the fusion model. Conclusion: The clinical-radiomics fusion model can effectively identify patients with HM-NENs sensitive to Surufatinib therapy. The nomogram provides clinicians with a convenient and dependable tool for decision-making.  \n1 | Introduction  \nNeuroendocrine neoplasms (NENs) are a heterogeneous group of tumors originating from neuroendocrine cells, characteristically differentiated and expressing neuroendocrine markers [1] . In recent years, the clinical detection rate of NENs has increased significantly with the advancement of diagnostic imaging technology and the popularity of health check-ups [2] . The liver is  \nthe most common site of metastasis for NENs, and the presence of HM-NENs typically indicates a poorer prognosis, with a significantly lower 5-year survival rate than that of those without hepatic metastasis [3–6] . The biological behaviors of HM-NENs are highly heterogeneous, with diverse clinical manifestations, and treatment options need to comprehensively consider a variety of factors such as tumor grading, staging, metastatic load, functional status, and genetic background.  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.  \n© 2026 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.  \nCancer Medicine, 2026; 15:e71931 1 o","cbCaiaOX2qzbSxf9","https://ap.wps.com/l/cbCaiaOX2qzbSxf9","pdf",1493612,12,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Disease background and clinical challenge\n## Current treatment landscape","[{\"question\":\"Why is predicting Surufatinib efficacy in HM-NENs clinically important?\",\"answer\":\"HM-NENs have few effective biomarkers and poorer survival outcomes. Predicting treatment response supports more accurate precision medicine decisions.\"},{\"question\":\"How was the clinical-radiomics fusion model constructed?\",\"answer\":\"Pretreatment NCCT radiomics features were extracted after manual ROI segmentation. LASSO selected features, and multivariable logistic regression combined Radscore with clinical characteristics to form a nomogram.\"},{\"question\":\"What performance did the fusion model achieve?\",\"answer\":\"The model reached an AUC of 0.926 (95% CI: 0.881–0.971) for response prediction, with bootstrap-verified AUC of 0.926 (95% CI: 0.880–0.966).\"}]","Visualized Clinical-Radiomics Model Based on Non-Contrast Computed Tomography for Predicting Efficacy of Surufatinib in Hepatic Metastases of Neuroendocrine Neoplasms | PDF",1790127229,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/61c995ba8b87d23500da076633c7b187.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e8d3f5be12fc85742cfb2f97ae02ecd.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/81d44633835f72cbb0fe9c542fb755b7.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/631d84cbf78a31fa8f7329534f4b47ab.webp",980,1287]